PassiVe Immunization with an mAb
Journal of Medicinal Chemistry, 2008, Vol. 51, No. 21 6875
2-amino-N-methoxy-N-methylbenzamide. J. Org. Chem. 1991, 56,
3750–3752.
(22) Carpino, L. A. 1-Hydroxy-7-azabenzotriazole. An efficient peptide
coupling additive. J. Am. Chem. Soc. 1993, 115, 4397–4398.
(23) Sternbach, L. H.; Fryer, R. I.; Metlesics, W.; Sach, G.; Stempel, A.
Quinazolines and 1,4-benzodiazepines. V. o-Aminobenzophenones. J.
Org. Chem. 1962, 27 (11), 3781–3788.
(24) Sternbach, L. H.; Fryer, R. I.; Keller, O.; Metlesics, W.; Sach, G.;
Steiger, N. Quinazolinesand 1,4-benzodiazepines. X. Nitro-substituted
5-phenyl-1,4-benzodiazepine derivatives. J. Med. Chem. 1963, 6, 261–
265.
(25) Carrera, M. R. A.; Ashley, J. A.; Parsons, L. H.; Wirshing, P.; Koob,
G. F.; Janda, K. D. Suppression of psychoactive effects of cocaine by
active immunization. Nature 1995, 378 (6558), 727–730.
(26) Carrera, M. R. A.; Ashley, J. A.; Zhou, B.; Wirsching, P.; Koob, G. F.;
Janda, K. D. Cocaine vaccines: antibody protection against relapse in
a rat model. Proc. Natl. Acad. Sci. U.S.A. 2000, 97 (11), 6202–6206.
(27) Deroche, V.; Caine, S. B.; Heyser, C. J.; Polis, I.; Koob, G. F.; Gold,
L. H. Differences in the liability to self-administer intravenous cocaine
between C57BL/6 × SJL and BALB/cByJ mice. Pharmacol., Biochem.
BehaV. 1997, 57 (3), 429–440.
(28) Isomura, S.; Wirsching, P.; Janda, K. D. An immunotherapeutic
program for the treatment of nicotine addiction: hapten design and
synthesis. J. Org. Chem. 2001, 66 (12), 4115–4121.
(29) Matsushita, M.; Hoffman, T. Z.; Ashley, J. A.; Zhou, B.; Wirsching,
P.; Janda, K. D. Cocaine catalytic antibodies: the primary importance
of linker effects. Bioorg. Med. Chem. Lett. 2001, 11 (2), 87–90.
(30) Meijler, M. M.; Matsushita, M.; Altobell, L. J., III.; Wirsching, P.;
Janda, K. D. A new strategy for improved nicotine vaccines using
conformationally constrained haptens. J. Am. Chem. Soc. 2003, 125
(47), 164–165.
(31) Ino, A.; Dickerson, T. J.; Janda, K. D. Positional linker effects in
haptens for cocaine immunopharmacotherapy. Bioorg. Med. Chem.
Lett. 2007, 17 (15), 4280–4283.
(32) Qi, L.; Yamamoto, N.; Meijler, M. M.; Altobell, L. J.; Koob, G. F.;
Wirsching, P.; Janda, K. D. Delta-9-tetrahydrocannabinol immu-
nochemical studies: haptens, monoclonal antibodies, and a convenient
synthesis of radiolabeled delta-9-tetrahydrocannabinol. J. Med. Chem.
2005, 48 (23), 7389–7399.
(33) Fryer, R. I.; Gu, Z. Q. The rational design and synthesis of haptens
having specific activity as full agonists or full antagonists at the
benzodiazepine receptor. Life Sci. 1990, 47 (10), 833–840.
(34) Peterson, E. C.; Gunnell, M.; Che, Y.; Goforth, R. L.; Carroll, F. I.;
Henry, R.; Liu, H.; Owens, S. M. Using hapten design to discover
therapeutic monoclonal antibodies for treating methamphetamine
abuse. J. Pharmacol. Exp. Ther. 2007, 322 (1), 30–39.
(35) Castellano, C.; Pavone, F. Effects of flunitrazepam on passive
avoidance behaviour in mice subjected to immobilization stress or
familiarized with the testing apparatus. BehaV. Brain Res. 1986, 22
(1), 91–95.
(36) Bowers, B. J.; Elliott, K. J.; Wehner, J. M. Differential sensitivity to
the anxiolytic effects of ethanol and flunitrazepam in PKCgamma null
mutant mice. Pharmacol., Biochem. BehaV. 2001, 69, 99–110.
(37) Savic´, M. M.; Obradovic´, D. I.; Ugresic´, N. D.; Cook, J. M.; Yin,
W.; Van Linn, M.; Bokonjic´, D. R. Benzodiazepine site inverse
agonists and locomotor activity in rats: bimodal and biphasic influence.
Pharmacol., Biochem. BehaV. 2006, 84 (1), 35–42.
(38) DeLorey, T. M.; Lin, R. C.; McBrady, B.; He, X.; Cook, J. M.; Lameh,
J.; Loew, G. H. Influence of benzodiazepine binding site ligands on
fear-conditioned contextual memory. Eur. J. Pharmacol. 2001, 426
(1-2), 45–54.
(39) Blanchard, D. C.; Griebel, G.; Blanchard, R. J. The mouse defense
test battery: pharmacological and behavioral assays for anxiety and
panic. Eur. J. Pharmacol. 2003, 463 (1-3), 97–116.
National Institute on Drug Abuse (Grant DA 21939 to J.B.T.,
Grant DA 98590 to K.D.J.).
Supporting Information Available: 1H and 13C NMR spectra
and HPLC traces of compounds 4-6 and the RCA hapten. This
material is available free of charge via the Internet at http://
pubs.acs.org.
References
(1) Meijler, M. M.; Matsushita, M.; Wirsching, P.; Janda, K. D. Develop-
ment of immunopharmacotherapy against drugs of abuse. Curr. Drug
DiscoVery Technol. 2004, 1 (1), 77–89.
(2) Kosten, T.; Owens, S. M. Immunotherapy for the treatment of drug
abuse. Pharmacol. Ther. 2005, 108 (1), 76–85.
(3) Pentel, P. R.; Dufek, M. B.; Roiko, S. A.; Lesage, M. G.; Keyler,
D. E. Differential effects of passive immunization with nicotine-specific
antibodies on the acute and chronic distribution of nicotine to brain
in rats. J. Pharmacol. Exp. Ther. 2006, 317 (2), 660–666.
(4) Utzinger, R. Hapten-immunological studies on mescaline. Psychop-
harmacologia 1975, 41 (3), 301–304.
(5) Fox, B. S.; Kantak, K. M.; Edwards, M. A.; Black, K. M.; Bollinger,
B. K.; Botka, A. J.; French, T. L.; Thompson, T. L.; Schad, V. C.;
Greenstein, J. L.; Gefter, M. L.; Exley, M. A.; Swain, P. A.; Briner,
T. J. Efficacy of a therapeutic cocaine vaccine in rodent models. Nat.
Med. 1996, 2, 1129–1132.
(6) Valentine, J. L.; Mayersohn, M.; Wessinger, W. D.; Arnold, L. W.;
Owens, S. M. Antiphencyclidine monoclonal Fab fragments reverse
phencyclidine-induced behavioral effects and ataxia in rats. J. Phar-
macol. Exp. Ther. 1996, 278 (2), 709–716.
(7) Kantak, K. M.; Collins, S. L.; Lipman, E. G.; Bond, J.; Giovanoni,
K.; Fox, B. S. Evaluation of anti-cocaine antibodies and a cocaine
vaccine in a rat self-administration model. Psychopharmacology 2000,
148 (3), 251–262.
(8) Hardin, J. S.; Wessinger, W. D.; Wenger, G. R.; Proksch, J. W.;
Laurenzana, E., M.; Owens, S. M. A single dose of monoclonal anti-
phencyclidine IgG offers long-term reductions in phencyclidine
behavioral effects in rats. J. Pharmacol. Exp. Ther. 2002, 302, 119–
126.
(9) Gentry, W. B.; Laurenzana, E. M.; Williams, D. K.; West, J. R.; Berg,
R. J.; Terlea, T.; Owens, S. M. Safety and efficiency of an anti-(+)-
methamphetamine monoclonal antibody in the protection against
cardiovascular and central nervous system effects of (+)-metham-
phetamine in rats. Int. Immunopharmacol. 2006, 6, 968–977.
(10) Carrera, M. R. A.; Trigo, J. M.; Wirshing, P.; Roberts, A. J.; Janda,
K. D. Evaluation of the anticocaine monoclonal antibody GNC92H2
as an immunotherapy for cocaine overdose. Pharmacol., Biochem.
BehaV. 2005, 81, 709–714.
(11) Malin, D. H.; Lake, J. R.; Lin, A.; Saldana, M.; Balch, L.; Irvin,
M. L. L.; Chandrasekara, H.; Alvarado, C. L.; Hieda, Y.; Keyler, D. E.
Passive immunization against nicotine prevents nicotine alleviation
of nicotine abstinence syndrome. Pharmacol., Biochem. BehaV. 2001,
68 (1), 87–92.
(12) Mattila, M. A. K.; Larni, H. M. Flunitrazepam: a review of its
pharmacological properties and therapeutic use. Drugs 1980, 20 (5),
353–374.
(13) Berezhnoy, D.; Nyfeler, Y.; Gonthier, A.; Schwob, H.; Goeldner, M.;
Sigel, E. On the benzodiazepine binding pocket in GABAA receptors.
J. Biol. Chem. 2004, 279 (5), 3160–3168.
(14) Drummer, O. H.; Syrjanen, M. L.; Cordner, S. M. Deaths involving
the benzodiazepine flunitrazepam. Am. J. Forensic Med. Pathol. 1993,
14 (3), 238–243.
(15) Farre, M.; Teran, M.-T.; Roset, P. N.; Mas, M.; Torrens, M.; Cami, J.
Abuse liability of flunitrazepam among methadone-maintained patients.
Psychopharmacology 1998, 140, 486–495.
(16) Gambi, F.; Conti, C. M.; Grimaldi, M. R.; Giampietro, L.; De
Bernardis, B.; Ferro, F. M. Flunitrazepam a benzodiazepine most used
among drug abusers. Int. J. Immunopathol. Pharmacol. 1999, 12 (3),
157–159.
(17) Mintzer, M. Z.; Griffiths, R. R. An abuse liability comparison of
flunitrazepam and triazolam in sedative drug abusers. BehaV. Phar-
macol. 2005, 16 (7), 579–584.
(18) Schwartz, R. H.; Weaver, A. B. Rohypnol, the date rape drug. Clin.
Pediatr. 1998, 37, 321.
(40) Guscott, M. R.; Cook, G. P.; Bristow, L. J. Contextual fear conditioning
and baseline startle responses in the rat fear-potentiated startle test: a
comparison of benzodiazepine/gamma-aminobutyric acid-A receptor
agonists. BehaV. Pharmacol. 2000, 11 (6), 495–504.
(41) Brignell, C. M.; Curran, H. V. Drugs, sweat, and fears: a comparison
of the effects of diazepam and methylphenidate on fear conditioning.
Psychopharmacology 2006, 186 (4), 504–516.
(42) Fendt, M.; Fanselow, M. S. The neuroanatomical and neurochemical
basis of conditioned fear. Neurosci. BehaV. ReV. 1999, 23 (5), 743–
760.
(43) Harris, J. A.; Westbrook, R. F. Contextual control over the expression
of fear in rats conditioned under a benzodiazepine. Psychopharma-
cology 2001, 156, 92–97.
(19) Smith, K. M. Drugs used in acquaintance rape. J. Am. Pharm. Assoc.
1999, 39, 519–583.
(20) DEA Congressional Testimony, House Commerce Committee Sub-
committee on Oversight and Investigations, 106th Congress, 1st
Session; U.S. Drug Enforcement Administration: Springfield, VA,
1999.
(44) Harris, J. A.; Westbrook, R. F. The benzodiazepine midazolam does
not impair Pavlovian fear conditioning but regulates when and where
that fear is expressed. J. Exp. Psychol. Anim. BehaV. Process 1999,
25, 236–246.
(21) Frye, S. V.; Johnson, M. C.; Valvano, N. L. Synthesis of 2-aminoben-
zophenones via rapid halogen-lithium exchange in the presence of a
JM800506V